COLL
Collegium Pharmaceutical, Inc.$34.07+0.45 (+1.34%)Prev Close$33.62·MCap$1.09B·P/E16.64·Vol35.5K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
5
$2.33M
◆
Net Activity
Net Seller
$2.33M
●
Active Insiders
5
last 12 mo
Over the past 12 months, insider activity at Collegium Pharmaceutical, Inc. (COLL) has been exclusively selling, with 0 insider purchases totaling $0.00 and 5 insider sales totaling $2.33M. The most recent insider transaction was by Freund John Gordon (director), who sold $142.5K worth of shares on May 18, 2026. Collegium Pharmaceutical, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $1.09B.
COLL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Freund John Gordon | director | Sell | 4,127 | $34.54 | $142.5K | 83,972 |
| May 15, 2026 | Lurker Nancy | director | Sell | 4,500 | $35.97 | $161.9K | 18,017 |
| May 13, 2026 | BOHLIN GAREN G | director | Sell | 8,700 | $37.18 | $323.5K | 62,259 |
| Mar 20, 2026 | Dieter David | officer: EVP & General Counsel | Sell | 13,976 | $34.92 | $488.1K | 77,071 |
| Nov 6, 2025 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 30,000 | $40.53 | $1.22M | 0 |
| Mar 14, 2025 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 2,255 | $30.00 | $67.7K | 0 |
| Mar 11, 2025 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 15,387 | $30.00 | $461.7K | 0 |
| Jan 14, 2025 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 27,500 | $33.04 | $908.6K | 125,284 |
| Sep 17, 2024 | Smith Thomas B | EVP and Chief Medical Officer | Sell | 9,593 | $36.62 | $351.3K | 53,816 |
| Sep 6, 2024 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 20,225 | $38.26 | $773.8K | 122,561 |
| Jun 5, 2024 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 25,000 | $32.57 | $814.2K | 140,109 |
| May 29, 2024 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 19,710 | $34.21 | $674.4K | 130,845 |
| May 28, 2024 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 108,016 | $33.91 | $3.66M | 138,918-44% |
| May 16, 2024 | BOHLIN GAREN G | Director | Sell | 28,985 | $32.30 | $936.3K | 44,775-39% |
| Mar 4, 2024 | Smith Thomas B | EVP and Chief Medical Officer | Sell | 995 | $36.76 | $36.6K | 63,409 |
| Feb 28, 2024 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 10,000 | $36.43 | $364.3K | 139,582 |
| Jan 18, 2024 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 23,560 | $32.28 | $760.5K | 111,322 |
| Dec 22, 2023 | Ciaffoni Joseph | President and CEO | Sell | 4,357 | $30.38 | $132.4K | 275,000 |
| Dec 20, 2023 | Ciaffoni Joseph | President and CEO | Sell | 68,768 | $30.18 | $2.08M | 275,000 |
| Nov 29, 2023 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 25,600 | $25.78 | $660.0K | 119,518 |
| Jun 28, 2023 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 17,984 | $21.72 | $390.6K | 120,881 |
| Jun 2, 2023 | Ciaffoni Joseph | President and CEO | Sell | 62,544 | $21.84 | $1.37M | 306,272 |
| Jun 1, 2023 | Ciaffoni Joseph | President and CEO | Sell | 62,543 | $21.88 | $1.37M | 368,816 |
| Mar 17, 2023 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 31,640 | $23.77 | $752.2K | 105,420 |
| Mar 3, 2023 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 13,324 | $26.70 | $355.8K | 134,882 |
| Feb 14, 2023 | Ciaffoni Joseph | President and CEO | Sell | 11,250 | $26.88 | $302.4K | 400,087 |
| Feb 14, 2023 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 21,811 | $26.88 | $586.3K | 137,502 |
| Jan 11, 2023 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 17,834 | $27.39 | $488.6K | 110,208 |
| Dec 27, 2022 | Ciaffoni Joseph | President and CEO | Sell | 2,461 | $23.67 | $58.3K | 251,101 |
| Dec 27, 2022 | Heffernan Michael Thomas | Director | Sell | 25,041 | $23.58 | $590.5K | 28,023-47% |
| Dec 21, 2022 | Ciaffoni Joseph | President and CEO | Sell | 17,842 | $23.08 | $411.8K | 267,919 |
| Dec 21, 2022 | Heffernan Michael Thomas | Director | Sell | 83,964 | $23.09 | $1.94M | 28,023-75% |
| Dec 14, 2022 | Heffernan Michael Thomas | Director | Sell | 189,607 | $22.14 | $4.20M0.6% OS | 28,023-87% |
| Dec 5, 2022 | Ciaffoni Joseph | President and CEO | Sell | 131,053 | $22.72 | $2.98M | 323,453-29% |
| Nov 30, 2022 | Ciaffoni Joseph | President and CEO | Sell | 43 | $22.00 | $946.00 | 323,453 |
| Nov 25, 2022 | Ciaffoni Joseph | President and CEO | Sell | 65 | $22.00 | $1.4K | 323,453 |
| Nov 22, 2022 | Ciaffoni Joseph | President and CEO | Sell | 1,989 | $22.02 | $43.8K | 323,453 |
| Oct 6, 2022 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 4,350 | $17.35 | $75.5K | 90,304 |
| Sep 16, 2022 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 38,589 | $18.07 | $697.3K | 109,495-26% |
| Aug 15, 2022 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 300 | $20.01 | $6.0K | 148,084 |
| Mar 3, 2022 | Ciaffoni Joseph | President and CEO | Sell | 76,094 | $18.47 | $1.41M | 335,858 |
| Feb 28, 2022 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 10,559 | $21.61 | $228.2K | 121,226 |
| Dec 17, 2021 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 5,693 | $18.33 | $104.4K | 76,970 |
| Jun 3, 2021 | Ciaffoni Joseph | President and CEO | Sell | 22,066 | $23.09 | $509.6K | 284,464 |
| May 12, 2021 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 7,000 | $22.77 | $159.4K | 89,990 |
| Mar 17, 2021 | Heffernan Michael Thomas | Director | Sell | 50,075 | $25.30 | $1.27M | 7,078-88% |
| Mar 3, 2021 | Ciaffoni Joseph | President and CEO | Sell | 64,768 | $22.67 | $1.47M | 288,116 |
| Mar 3, 2021 | Fleming Alison B | Chief Technical Officer | Sell | 6,011 | $23.36 | $140.4K | 148,753 |
COLL Insider Buying Activity
The following table shows recent insider purchases of Collegium Pharmaceutical, Inc. (COLL) stock reported via SEC Form 4 filings.
No insider buying activity found for COLL in the last 12 months.
COLL Insider Selling Activity
The following table shows recent insider sales of Collegium Pharmaceutical, Inc. (COLL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Freund John Gordon | director | Sell | 4,127 | $34.54 | $142.5K | 83,972 |
| May 15, 2026 | Lurker Nancy | director | Sell | 4,500 | $35.97 | $161.9K | 18,017 |
| May 13, 2026 | BOHLIN GAREN G | director | Sell | 8,700 | $37.18 | $323.5K | 62,259 |
| Mar 20, 2026 | Dieter David | officer: EVP & General Counsel | Sell | 13,976 | $34.92 | $488.1K | 77,071 |
| Nov 6, 2025 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 30,000 | $40.53 | $1.22M | 0 |
| Mar 14, 2025 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 2,255 | $30.00 | $67.7K | 0 |
| Mar 11, 2025 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 15,387 | $30.00 | $461.7K | 0 |
| Jan 14, 2025 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 27,500 | $33.04 | $908.6K | 125,284 |
| Sep 17, 2024 | Smith Thomas B | EVP and Chief Medical Officer | Sell | 9,593 | $36.62 | $351.3K | 53,816 |
| Sep 6, 2024 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 20,225 | $38.26 | $773.8K | 122,561 |
| Jun 5, 2024 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 25,000 | $32.57 | $814.2K | 140,109 |
| May 29, 2024 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 19,710 | $34.21 | $674.4K | 130,845 |
| May 28, 2024 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 108,016 | $33.91 | $3.66M | 138,918-44% |
| May 16, 2024 | BOHLIN GAREN G | Director | Sell | 28,985 | $32.30 | $936.3K | 44,775-39% |
| Mar 4, 2024 | Smith Thomas B | EVP and Chief Medical Officer | Sell | 995 | $36.76 | $36.6K | 63,409 |
| Feb 28, 2024 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 10,000 | $36.43 | $364.3K | 139,582 |
| Jan 18, 2024 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 23,560 | $32.28 | $760.5K | 111,322 |
| Dec 22, 2023 | Ciaffoni Joseph | President and CEO | Sell | 4,357 | $30.38 | $132.4K | 275,000 |
| Dec 20, 2023 | Ciaffoni Joseph | President and CEO | Sell | 68,768 | $30.18 | $2.08M | 275,000 |
| Nov 29, 2023 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 25,600 | $25.78 | $660.0K | 119,518 |
| Jun 28, 2023 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 17,984 | $21.72 | $390.6K | 120,881 |
| Jun 2, 2023 | Ciaffoni Joseph | President and CEO | Sell | 62,544 | $21.84 | $1.37M | 306,272 |
| Jun 1, 2023 | Ciaffoni Joseph | President and CEO | Sell | 62,543 | $21.88 | $1.37M | 368,816 |
| Mar 17, 2023 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 31,640 | $23.77 | $752.2K | 105,420 |
| Mar 3, 2023 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 13,324 | $26.70 | $355.8K | 134,882 |
| Feb 14, 2023 | Ciaffoni Joseph | President and CEO | Sell | 11,250 | $26.88 | $302.4K | 400,087 |
| Feb 14, 2023 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 21,811 | $26.88 | $586.3K | 137,502 |
| Jan 11, 2023 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 17,834 | $27.39 | $488.6K | 110,208 |
| Dec 27, 2022 | Ciaffoni Joseph | President and CEO | Sell | 2,461 | $23.67 | $58.3K | 251,101 |
| Dec 27, 2022 | Heffernan Michael Thomas | Director | Sell | 25,041 | $23.58 | $590.5K | 28,023-47% |
| Dec 21, 2022 | Ciaffoni Joseph | President and CEO | Sell | 17,842 | $23.08 | $411.8K | 267,919 |
| Dec 21, 2022 | Heffernan Michael Thomas | Director | Sell | 83,964 | $23.09 | $1.94M | 28,023-75% |
| Dec 14, 2022 | Heffernan Michael Thomas | Director | Sell | 189,607 | $22.14 | $4.20M0.6% OS | 28,023-87% |
| Dec 5, 2022 | Ciaffoni Joseph | President and CEO | Sell | 131,053 | $22.72 | $2.98M | 323,453-29% |
| Nov 30, 2022 | Ciaffoni Joseph | President and CEO | Sell | 43 | $22.00 | $946.00 | 323,453 |
| Nov 25, 2022 | Ciaffoni Joseph | President and CEO | Sell | 65 | $22.00 | $1.4K | 323,453 |
| Nov 22, 2022 | Ciaffoni Joseph | President and CEO | Sell | 1,989 | $22.02 | $43.8K | 323,453 |
| Oct 6, 2022 | Tupper Colleen | EVP & Chief Financial Officer | Sell | 4,350 | $17.35 | $75.5K | 90,304 |
| Sep 16, 2022 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 38,589 | $18.07 | $697.3K | 109,495-26% |
| Aug 15, 2022 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 300 | $20.01 | $6.0K | 148,084 |
| Mar 3, 2022 | Ciaffoni Joseph | President and CEO | Sell | 76,094 | $18.47 | $1.41M | 335,858 |
| Feb 28, 2022 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 10,559 | $21.61 | $228.2K | 121,226 |
| Dec 17, 2021 | Dreyer Scott | EVP & Chief Commercial Officer | Sell | 5,693 | $18.33 | $104.4K | 76,970 |
| Jun 3, 2021 | Ciaffoni Joseph | President and CEO | Sell | 22,066 | $23.09 | $509.6K | 284,464 |
| May 12, 2021 | Kuhlmann Shirley R. | EVP and General Counsel | Sell | 7,000 | $22.77 | $159.4K | 89,990 |
| Mar 17, 2021 | Heffernan Michael Thomas | Director | Sell | 50,075 | $25.30 | $1.27M | 7,078-88% |
| Mar 3, 2021 | Ciaffoni Joseph | President and CEO | Sell | 64,768 | $22.67 | $1.47M | 288,116 |
| Mar 3, 2021 | Fleming Alison B | Chief Technical Officer | Sell | 6,011 | $23.36 | $140.4K | 148,753 |
COLL Insiders
Similar Stocks to COLL
ZTS
Zoetis Inc.
$78.86-0.08%
$31.64B
VTRS
Viatris Inc.
$16.42+1.45%
$19.19B
ELAN
Elanco Animal Health Incorporated
$20.82+5.51%
$9.92B
INDV
Indivior Pharmaceuticals Inc
$37.88+2.39%
$4.56B
AMRX
Amneal Pharmaceuticals, Inc.
$12.12+2.54%
$3.80B
SUPN
Supernus Pharmaceuticals, Inc.
$48.38+2.01%
$2.81B
ANIP
ANI Pharmaceuticals, Inc.
$81.60+1.59%
$1.77B
PAHC
Phibro Animal Health Corporation
$34.50+1.77%
$1.39B